Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NVO · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Bod… NCT07931599 · Diabetes Mellitus, Type 2 Zenagamtide, Semaglutide | NVO Novo Nordisk A/S | Phase 3 | Not yet recruiting | 1,060 | Jul 24, 2028 | Registry ↗ |
| Nov 12, 2026 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood… NCT07931573 · Type 2 Diabetes Zenagamtide, Semaglutide | NVO Novo Nordisk A/S | Phase 3 | Not yet recruiting | 1,200 | Jul 4, 2028 | Registry ↗ |
| Nov 12, 2026 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to… NCT07931547 · Type 2 Diabetes, Chronic Kidney Disease Placebo, Zenagamtide | NVO Novo Nordisk A/S | Phase 3 | Not yet recruiting | 450 | Jul 31, 2028 | Registry ↗ |
| Nov 12, 2026 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to… NCT07931495 · Diabetes Mellitus, Type 2 Zenagamtide, Placebo | NVO Novo Nordisk A/S | Phase 3 | Not yet recruiting | 200 | Jun 5, 2028 | Registry ↗ |
| Nov 10, 2026 | A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Partici… NCT07896109 · Diabetes Mellitus, Type 2 NNC9836-0001, Placebo (NaCl) | NVO Novo Nordisk A/S | Phase 1 | Recruiting was not yet recruiting | 121 | Jul 26, 2028 | Registry ↗ |
| Nov 10, 2026 | A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it… NCT07587710 · Overweight, Obesity NNC0487-0111 | NVO Novo Nordisk A/S | Phase 1 | Recruiting was not yet recruiting | 35 | Dec 1, 2027 | Registry ↗ |
| Nov 10, 2026 | AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide… NCT07400107 · Obesity, Overweight NNC0487-0111, Semaglutide | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting was not yet recruiting | 985 | Dec 19, 2028 | Registry ↗ |
| Nov 6, 2026 | AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess… NCT07533175 · Diabetes Mellitus, Overweight NNC0487-0111, Placebo (matched to NNC0487-0111) | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting was recruiting | 638 | Aug 7, 2028 | Registry ↗ |
| Nov 5, 2026 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in Peopl… NCT07919405 · Hypertension, Obesity CagriSema, Semaglutide | NVO Novo Nordisk A/S | Phase 3 | Not yet recruiting | 1,408 | Jun 1, 2028 | Registry ↗ |
| Nov 4, 2026 | Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney… NCT04968184 · Chronic Kidney Diseases Placebo, KBP-5074 | NVO Novo Nordisk A/S | Phase 3 | Terminated | 666 | Jan 30, 2024 | Registry ↗ |
| Nov 2, 2026 | Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity a… NCT04916470 · Heart Failure With Preserved Ejection Fraction (HFpEF) and… Semaglutide, Placebo (Semaglutide) | NVO Novo Nordisk A/S | Phase 3 | Completed | 617 | Oct 11, 2023 | Registry ↗ |
| Oct 28, 2026 | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidn… NCT07900438 · Cardiovascular Risk, Chronic Kidney Disease Semaglutide | NVO Novo Nordisk A/S | Phase 4 | Recruiting | 300 | Dec 20, 2029 | Registry ↗ |
| Oct 28, 2026 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A NCT07830732 · Haemophilia A Denecimig | NVO Novo Nordisk A/S | Phase 3 | Recruiting | 84 | Mar 23, 2029 | Registry ↗ |
| Oct 28, 2026 | Compassionate Use of Concizumab if You Have Haemophilia NCT04921956 · Congenital Haemophilia Concizumab | NVO Novo Nordisk A/S | — | No longer available | — | — | Registry ↗ |
| Oct 26, 2026 | A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People NCT07829406 · Healthy Volunteers NNC0642-1895, Placebo | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 148 | Sep 12, 2027 | Registry ↗ |
| Oct 26, 2026 | A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomati… NCT06859073 · Healthy Volunteers, Hyperuricemia NNC4004-0002, Placebo | NVO Novo Nordisk A/S | Phase 1 | Active, not recruiting | 50 | Jan 19, 2027 | Registry ↗ |
| Oct 22, 2026 | A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a W… NCT03811535 · Growth Hormone Deficiency in Children Somapacitan, Norditropin® | NVO Novo Nordisk A/S | Phase 3 | Completed | 200 | Nov 10, 2021 | Registry ↗ |
| Oct 21, 2026 | CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (… NCT07207811 · Transthyretin Amyloid Cardiomyopathy (ATTR CM) NNC6019-0001, Placebo (NNC6019-0001) | NVO Novo Nordisk A/S | Phase 3 | Recruiting | 1,280 | Jun 29, 2029 | Registry ↗ |
| Oct 19, 2026 | Semaglutide Health Outcomes and Patient Adherence in Australia NCT07881770 · Overweight, Obesity Semaglutide | NVO Novo Nordisk A/S | — | Not yet recruiting | 10,000 | Feb 28, 2028 | Registry ↗ |
| Oct 19, 2026 | Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Du… NCT07607587 · Obesity, Overweight Cagrilintide, Placebo (matched to Cagrilintide) | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 114 | Nov 19, 2027 | Registry ↗ |
| Oct 19, 2026 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo i… NCT07282613 · Diabetes Mellitus, Type 2 CagriSema (Cagrilintide B and Semaglutide I), Placebo match… | NVO Novo Nordisk A/S | Phase 3 | Recruiting | 80 | Sep 7, 2029 | Registry ↗ |
| Oct 19, 2026 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepati… NCT06534411 · Diabetes Mellitus, Type 2 Cagrilintide, Semaglutide | NVO Novo Nordisk A/S | Phase 3 | Completed | 1,023 | Jun 2, 2026 | Registry ↗ |
| Oct 19, 2026 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepati… NCT06221969 · Type 2 Diabetes Cagrilintide, Semaglutide | NVO Novo Nordisk A/S | Phase 3 | Completed | 1,024 | Mar 4, 2026 | Registry ↗ |
| Oct 16, 2026 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabet… NCT07868354 · Overweight, Obesity Tirzepatide, Zenagamtide | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 60 | Sep 7, 2028 | Registry ↗ |
| Oct 16, 2026 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabet… NCT07855133 · Overweight, Obesity Semaglutide, Zenagamtide | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 60 | Sep 6, 2028 | Registry ↗ |
| Oct 13, 2026 | A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants… NCT07214870 · Fatty Liver Disease NNC4005-001, Placebo | NVO Novo Nordisk A/S | Phase 1 | Active, not recruiting | 29 | May 14, 2027 | Registry ↗ |
| Oct 13, 2026 | Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) NCT04822181 · Non-alcoholic Steatohepatitis Semaglutide, Placebo | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting | 1,205 | Apr 25, 2029 | Registry ↗ |
| Oct 9, 2026 | A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who… NCT06260709 · Transthyretin Amyloid Cardiomyopathy (ATTR CM) NNC6019-0001 | NVO Novo Nordisk A/S | Phase 2 | Active, not recruiting | 88 | Feb 29, 2028 | Registry ↗ |
| Oct 8, 2026 | An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medic… NCT05621746 · Haemophilia A Esperoct | NVO Novo Nordisk A/S | — | Completed | 123 | Apr 30, 2026 | Registry ↗ |
| Oct 8, 2026 | French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Synd… NCT05308927 · Noonan Syndrome Norditropin | NVO Novo Nordisk A/S | — | Enrolling by invitation | 221 | Mar 17, 2028 | Registry ↗ |
| Oct 8, 2026 | Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol NCT04682145 · Haemophilia A Turoctocog alfa pegol | NVO Novo Nordisk A/S | — | Enrolling by invitation | 50 | Dec 1, 2026 | Registry ↗ |
| Oct 8, 2026 | Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Pa… NCT03972345 · Growth Hormone Deficiency in Children, Born Small for Gesta… Norditropin® FlexPro® | NVO Novo Nordisk A/S | — | Enrolling by invitation | 750 | Jun 30, 2029 | Registry ↗ |
| Oct 8, 2026 | Adverse Event Data Collection From External Registries on Nonacog Beta Pegol NCT03690336 · Haemophilia B Nonacog beta pegol | NVO Novo Nordisk A/S | — | Enrolling by invitation | 10 | Oct 1, 2027 | Registry ↗ |
| Oct 7, 2026 | A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on… NCT07815067 · Overweight, Obesity Zenagamtide injection, Zenagamtide tablet | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 320 | Jun 12, 2028 | Registry ↗ |
| Oct 7, 2026 | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in Peo… NCT07668388 · Diabetes Mellitus, Type 2 UBT251, UBT251 Placebo | NVO Novo Nordisk A/S | Phase 2 | Recruiting | 300 | Oct 4, 2027 | Registry ↗ |
| Oct 7, 2026 | AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess… NCT07571109 · Obesity, Overweight NNC0487-0111, Placebo (matched to NNC0487-0111) | NVO Novo Nordisk A/S | Phase 3 | Recruiting | 300 | Jun 26, 2028 | Registry ↗ |
| Oct 7, 2026 | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment Wit… NCT07220759 · Overweight, Obesity Cagrilintide, Placebo (matched to Cagrilintide) | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting | 330 | May 12, 2027 | Registry ↗ |
| Oct 7, 2026 | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose… NCT05726227 · Obesity Semaglutide, Placebo | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting | 212 | Oct 15, 2025 | Registry ↗ |
| Oct 7, 2026 | A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in Peo… NCT03811561 · Diabetes Mellitus, Type 2 Semaglutide, Placebo (semaglutide) | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting | 1,500 | Nov 7, 2027 | Registry ↗ |
| Oct 6, 2026 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Establish… NCT07861100 · Cardiovascular Risk, Obesity Zenagamtide, Placebo | NVO Novo Nordisk A/S | Phase 3 | Not yet recruiting | 8,500 | Sep 16, 2030 | Registry ↗ |
| Oct 6, 2026 | Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Ex… NCT07653139 · Haemophilia A No treatment given | NVO Novo Nordisk A/S | — | Enrolling by invitation | 150 | Dec 26, 2026 | Registry ↗ |
| Oct 6, 2026 | A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week… NCT03878446 · Short Stature Children Born Small for Gestational Age (SGA) Somapacitan, Norditropin® | NVO Novo Nordisk A/S | Phase 2 | Active, not recruiting | 62 | May 5, 2021 | Registry ↗ |
| Oct 5, 2026 | A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of… NCT06979362 · Heart Failure CDR132L, Placebo | NVO Novo Nordisk A/S | Phase 2 | Recruiting | 200 | Nov 16, 2027 | Registry ↗ |
| Oct 2, 2026 | A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar… NCT06542874 · Type 2 Diabetes (T2D) NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous) | NVO Novo Nordisk A/S | Phase 2 | Completed | 448 | Oct 1, 2025 | Registry ↗ |
| Oct 1, 2026 | A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adult… NCT07757087 · Overweight, Obesity NNC0487-0111, Placebo | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 120 | Sep 18, 2028 | Registry ↗ |
| Oct 1, 2026 | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart… NCT06200207 · Heart Failure, Systemic Inflammation Ziltivekimab, Placebo | NVO Novo Nordisk A/S | Phase 3 | Active, not recruiting | 673 | Oct 1, 2026 | Registry ↗ |
| Oct 1, 2026 | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure… NCT05636176 · Heart Failure Ziltivekimab, Placebo | NVO Novo Nordisk A/S | Phase 3 | Terminated | 4,874 | Sep 3, 2026 | Registry ↗ |
| Sep 30, 2026 | Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets NCT07850765 · Overweight, Obesity Semaglutide | NVO Novo Nordisk A/S | — | Completed | 1,260 | Aug 31, 2026 | Registry ↗ |
| Sep 30, 2026 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema NCT07817251 · Diabetes Mellitus, Type 2 CagriSema | NVO Novo Nordisk A/S | Phase 3 | Recruiting | 210 | Jun 9, 2027 | Registry ↗ |
| Sep 30, 2026 | A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People NCT07797855 · Healthy Volunteers, Cardiometabolic Diseases NNC0705-0002, Placebo | NVO Novo Nordisk A/S | Phase 1 | Recruiting | 112 | Aug 1, 2027 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:15 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances